US Medicare to reimburse use of cancer-matching service developed in Singapore

The cancer-matching service is able to match lung cancers to a targeted drug, should there be one. PHOTO ILLUSTRATION: PIXABAY
New: Gift this subscriber-only story to your friends and family

SINGAPORE – Several cancer-related organisations in Singapore are excited with the recent announcement that Medicare, the United States federal health insurance programme, will reimburse patients with advanced lung cancer who use a technology developed in Singapore.

Lucence, which has headquarters in Singapore and the US, said: “This approval establishes Lucence as the first and only Asian-headquartered healthcare services company to secure United States national insurance coverage.”

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Join ST's Telegram channel and get the latest breaking news delivered to you.